| Literature DB >> 34675076 |
Miaozhen Pan1,2, Fei Zhao1,2, Bintao Xie1,2, Hao Wu1,2, Sen Zhang1,2, Cong Ye1,3, Zhenqi Guan1,2, Lin Kang1,2, Yuqing Zhang1,2, Xuan Zhou1,2, Yi Lei1,2, Qi Wang1,2, Li Wang1,2, Fan Yang1,2, Chenchen Zhao1,2, Jia Qu4,2,3,5, Xiangtian Zhou4,2,3,5,6.
Abstract
Myopia is a leading cause of visual impairment and blindness worldwide. However, a safe and accessible approach for myopia control and prevention is currently unavailable. Here, we investigated the therapeutic effect of dietary supplements of omega-3 polyunsaturated fatty acids (ω-3 PUFAs) on myopia progression in animal models and on decreases in choroidal blood perfusion (ChBP) caused by near work, a risk factor for myopia in young adults. We demonstrated that daily gavage of ω-3 PUFAs (300 mg docosahexaenoic acid [DHA] plus 60 mg eicosapentaenoic acid [EPA]) significantly attenuated the development of form deprivation myopia in guinea pigs and mice, as well as of lens-induced myopia in guinea pigs. Peribulbar injections of DHA also inhibited myopia progression in form-deprived guinea pigs. The suppression of myopia in guinea pigs was accompanied by inhibition of the "ChBP reduction-scleral hypoxia cascade." Additionally, treatment with DHA or EPA antagonized hypoxia-induced myofibroblast transdifferentiation in cultured human scleral fibroblasts. In human subjects, oral administration of ω-3 PUFAs partially alleviated the near-work-induced decreases in ChBP. Therefore, evidence from these animal and human studies suggests ω-3 PUFAs are potential and readily available candidates for myopia control.Entities:
Keywords: choroidal blood perfusion; myofibroblast transdifferentiation; myopia; scleral hypoxia; ω-3 PUFAs
Mesh:
Substances:
Year: 2021 PMID: 34675076 PMCID: PMC8639353 DOI: 10.1073/pnas.2104689118
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205